The serum concentration of Bendamustine can be increased when it is combined with Midostaurin. Oleandrin may decrease the cardiotoxic activities of Bendamustine. The metabolism of Bendamustine can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bendamustine. Cyclophosphamide may increase the cardiotoxic activities of Bendamustine. The metabolism of Bendamustine can be decreased when combined with Lidocaine. The risk or severity of myelosuppression can be increased when Metamizole is combined with Bendamustine. The serum concentration of Bendamustine can be increased when it is combined with Abiraterone. Ouabain may decrease the cardiotoxic activities of Bendamustine. The serum concentration of Bendamustine can be decreased when it is combined with Teriflunomide. Digitoxin may decrease the cardiotoxic activities of Bendamustine. The serum concentration of Bendamustine can be increased when it is combined with Peginterferon alfa-2b. The metabolism of Bendamustine can be decreased when combined with Bortezomib. Deslanoside may decrease the cardiotoxic activities of Bendamustine. The metabolism of Bendamustine can be decreased when combined with Caffeine. Trastuzumab may increase the cardiotoxic activities of Bendamustine. The serum concentration of Bendamustine can be decreased when it is combined with Cyproterone acetate. Acetyldigitoxin may decrease the cardiotoxic activities of Bendamustine. The metabolism of Bendamustine can be decreased when combined with Ropinirole. The serum concentration of Bendamustine can be increased when it is combined with Mexiletine. The risk or severity of adverse effects can be increased when Allopurinol is combined with Bendamustine. The metabolism of Bendamustine can be decreased when combined with Ticlopidine. The metabolism of Bendamustine can be decreased when combined with Nevirapine. The serum concentration of Bendamustine can be decreased when it is combined with Osimertinib. The metabolism of Bendamustine can be decreased when combined with Citalopram. The metabolism of Bendamustine can be decreased when combined with Simeprevir. The metabolism of Bendamustine can be decreased when combined with Azithromycin. The serum concentration of Bendamustine can be increased when it is combined with Vemurafenib. The risk or severity of adverse effects can be increased when Docetaxel is combined with Bendamustine. Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bendamustine. The serum concentration of Bendamustine can be increased when it is combined with Deferasirox. The serum concentration of Bendamustine can be increased when it is combined with Dosulepin. Digoxin may decrease the cardiotoxic activities of Bendamustine. The risk or severity of adverse effects can be increased when Bendamustine is combined with Clozapine. The metabolism of Bendamustine can be decreased when combined with Lobeglitazone. The metabolism of Bendamustine can be decreased when combined with Rucaparib. Proscillaridin may decrease the cardiotoxic activities of Bendamustine. The metabolism of Bendamustine can be decreased when combined with Tenofovir disoproxil. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bendamustine. Bevacizumab may increase the cardiotoxic activities of Bendamustine. The metabolism of Bendamustine can be decreased when combined with Theophylline. The serum concentration of Bendamustine can be increased when it is combined with Fluvoxamine. The metabolism of Bendamustine can be decreased when combined with Zucapsaicin.